Status:
RECRUITING
PRP in ACLR to Prevent PTOA
Lead Sponsor:
Hospital for Special Surgery, New York
Collaborating Sponsors:
Orthopedic Research and Education Foundation
Conditions:
Anterior Cruciate Ligament Injuries
Post-traumatic Osteoarthritis
Eligibility:
All Genders
14-50 years
Phase:
PHASE3
Brief Summary
The purpose of our study is to examine the effect of platelet-rich-plasma (PRP) injection on the short-term resolution of post-injury inflammation (biomarkers) and improvement in joint function in pat...
Detailed Description
Anterior cruciate ligament (ACL) injury is one of the most common clinical problems among active individuals, with over 250,000 ACL reconstructions (ACLR) per year in the United States. Surgical recon...
Eligibility Criteria
Inclusion
- Acute ACL injury within 6 weeks of presentation
- Age 14-50
- Male or female
- Meniscus injury that can be treated with meniscectomy or repair (the lack of meniscus injury will not exclude patients)
Exclusion
- Prior ACL reconstruction
- Prior cartilage repair procedure
- Prior meniscus surgery within 12 months
- Prior steroid, hyaluronic acid, or PRP injection within 6 months
- Other ligament injury requiring repair
- Any cartilage lesion requiring repair
- Any cartilage lesion greater than grade 2 (partial thickness injury)
- History of inflammatory arthritis or joint sepsis
- Non English speakers
Key Trial Info
Start Date :
June 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT05412381
Start Date
June 27 2022
End Date
December 31 2025
Last Update
January 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital for Special Surgery
New York, New York, United States, 10021